SER-109（一种纯化的研究性微生物组疗法）的制造过程降低了冠状病毒从供体粪便传播的风险。
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool.
作者信息
McChalicher Christopher, Abdulaziz Ahmad, Zhou S Steve, Lombardo Mary-Jane, Hasson Brooke, Auniņš John G, McGovern Barbara H, Ege David S
机构信息
Seres Therapeutics, Cambridge, Massachusetts, USA.
Microbac Laboratories, Inc, Sterling, Virginia, USA.
出版信息
Open Forum Infect Dis. 2022 Sep 2;9(9):ofac448. doi: 10.1093/ofid/ofac448. eCollection 2022 Sep.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may present risk to patients treated with donor-derived microbiome therapies when appropriate manufacturing controls and inactivation processes are lacking. We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.
当缺乏适当的生产控制和灭活工艺时，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）可能会给接受供体来源微生物组疗法治疗的患者带来风险。我们报告称，SER-109是一种为降低复发风险而研发的纯化研究性微生物组疗法，其生产步骤可灭活猪流行性腹泻病毒，这是SARS-CoV-2的一种模型冠状病毒。
Zotero 插件